BRANMOOR
THURSDAY · 14 MAY 2026

FDA Recall D-0344-2018

Primus Pharmaceuticals, Inc. · Scottsdale, AZ

Class I — life-threatening Terminated 536 days on record

Highest impact — Class I recall — FDA determination of strong likelihood of serious adverse health consequence or death.

Product

Limbrel (flavocoxid 250 mg) capsules, 60-count bottle, Rx only, Manufactured for: Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253; Manufactured by: Cornerstone Research and Development, Ogden, UT 84404, NDC 68040-601-16.

Lot / code: All lots within expiry.

Quantity: 7,826 bottles

Reason for recall

Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.

Recall record

Recall number
D-0344-2018
Classification
Class I
Status
Terminated
Voluntary or mandated
Voluntary: Firm initiated
Firm notification
Press Release
Distribution
Nationwide in the USA.
Recall initiated
2018-01-26
Classified by FDA Center
2018-02-09
FDA published
2018-02-21
Terminated
2019-07-16
Recalling firm
Primus Pharmaceuticals, Inc.
Firm location
Scottsdale, AZ

‹ All recalls